

















ABOUT THE SCIENCE BASED TARGETS INITIATIVE

The Science Based Targets initiative (SBTi) is a global body enabling companies and financial institutions to set ambitious emissions reduction targets in line with the latest climate science. The SBTi's goal is to accelerate businesses across the world to support the global economy to halve emissions before 2030 and achieve net-zero before 2050.

The initiative is a collaboration between CDP, the United Nations Global Compact, World Resources Institute (WRI) and the World Wide Fund for Nature (WWF) and one of the We Mean Business Coalition commitments. The SBTi defines and promotes best practice in science-based target setting, offers resources and guidance to reduce barriers to adoption, and independently assesses and approves companies' targets.

SBTI GLOBAL MOMENTUM BY THE NUMBERS





INTRODUCTION

This report presents the results and recommendations of the submitted targets assessed against the SBTi Criteria and guidance. This includes an overview of the GHG emissions sources and inventory, target setting methodologies and ambition, emissions included in the target boundary, and company-specific feedback from the validation process, if applicable. A detailed overview of the criteria is provided in the appendix. The approved target language, which will be listed on the SBTi website and should be used in all company communications, is as follows:


Hamilton Medical AG commits to reduce absolute scope 1 and 2 GHG emissions 42% by 2030 from a 2020 base year.* Hamilton Medical AG commits to reduce scope 3 GHG emissions 52% per CHF value added within the same timeframe.

*The target boundary includes biogenic land-related emissions and removals from bioenergy feedstocks.

The SBTi's Target Validation Team has classified Hamilton Medical AG's scope 1 and 2 target ambition and has determined it is in line with 1.5C trajectory.

GHG INVENTORY OVERVIEW

Hamilton Medical AG has submitted one GHG inventory for review by SBTi's Target Validation Team. In the calendar year of 2020 the company has reported total of 144,341 GHG emissions (tCO2e) in the full minimum boundary (scopes 1, 2 and 3). Hamilton Medical AG has reported no emissions outside of minimum boundary. Hamilton Medical AG has reported no emissions from the combustion, processing and distribution phase of bioenergy and the land use emissions and removals, associated with bioenergy feedstocks. The full breakdown of Hamilton Medical AG's GHG inventory, including biogenic emissions, is provided below.



OVERVIEW OF NEAR-TERM SCIENCE-BASED TARGETS

Hamilton Medical AG has submitted 2 near-term targets for review by the SBTi. All targets have been assessed against the SBTi's quantitative and qualitative criteria, along with the Target Validation Protocol. For approval, a company's targets must comply with all applicable requirements. The following is an overview of the approved targets:

Target wording	Public?	Base year	Most recent year	Target year	Туре	Target value	Method used
Hamilton Medical AG commits to reduce absolute scope 1 and 2 GHG emissions 42% by 2030 from a 2020 base year.* *The target boundary includes biogenic land-related emissions and removals from bioenergy feedstocks.	Yes	2020	2020	2030	Absolute	42.0%	Absolute contraction
Hamilton Medical AG commits to reduce scope 3 GHG emissions 52% per CHF value added by 2030 from a 2020 base year.	Yes	2020	2020	2030	Intensity	52.0%	Economic intensity (GEVA)


OVERVIEW OF NEAR-TERM SCIENCE-BASED TARGETS

Hamilton Medical AG commits to reduce absolute scope 1 and 2 GHG emissions 42% by 2030 from a 2020 base year.* *The target boundary includes biogenic land-related emissions and removals from bioenergy feedstocks.

Public: Yes

Temperature classification: 1.5°C

ABSOLUTE EMISSIONS



Target Coverage

GHG Inventory breakdown	Minimum boundary emissions	Outside minimum boundary	Biogenic Total
Scope 1	100.00%	N/A	N/A
Scope 2 market-based	100.00%	N/A	N/A
Scope 3 total	N/A	N/A	N/A
Purchased goods and services	N/A	N/A	N/A
2. Capital goods	N/A	N/A	N/A
3. Fuel- and energy-related activities	N/A	N/A	N/A
Upstream transportation and distribution	N/A	N/A	N/A
5. Waste generated in operations	N/A	N/A	N/A
6. Business travel	N/A	N/A	N/A
7. Employee commuting	N/A	N/A	N/A
8. Upstream leased assets	N/A	N/A	N/A
9. Downstream transportation and distribution	N/A	N/A	N/A
10. Processing of sold products	N/A	N/A	N/A
11. Use of sold products	N/A	N/A	N/A
12. End-of-life treatment of sold products	N/A	N/A	N/A
13. Downstream leased assets	N/A	N/A	N/A
14. Franchises	N/A	N/A	N/A
15. Investments	N/A	N/A	N/A


OVERVIEW OF NEAR-TERM SCIENCE-BASED TARGETS

Hamilton Medical AG commits to reduce scope 3 GHG emissions 52% per CHF value added by 2030 from a 2020 base year.

Target Year Activity: 2,141 Public: Yes

Temperature classification: N/A

EMISSIONS INTENSITY



Target Coverage

GHG Inventory breakdown	Minimum boundary emissions	Outside minimum boundary	Biogenic Total
Scope 1	N/A	N/A	N/A
Scope 2 market-based	N/A	N/A	N/A
Scope 3 total	69.42%	N/A	N/A
Purchased goods and services	61.50%	N/A	N/A
2. Capital goods	100.00%	N/A	N/A
3. Fuel- and energy-related activities	100.00%	N/A	N/A
4. Upstream transportation and distribution	100.00%	N/A	N/A
5. Waste generated in operations	100.00%	N/A	N/A
6. Business travel	100.00%	N/A	N/A
7. Employee commuting	100.00%	N/A	N/A
8. Upstream leased assets	N/A	N/A	N/A
Downstream transportation and distribution	N/A	N/A	N/A
10. Processing of sold products	N/A	N/A	N/A
11. Use of sold products	50.00%	N/A	N/A
12. End-of-life treatment of sold products	100.00%	N/A	N/A
13. Downstream leased assets	N/A	N/A	N/A
14. Franchises	N/A	N/A	N/A
15. Investments	N/A	N/A	N/A















